Activation of the PI3K/AKT pathway may contribute to tumorigenesis. AKT mediates survival signals that protect cells from apoptosis and, thus, is a potentially important therapeutic target. To determine the frequency of AKT activation in human ovarian cancer, we screened a tumor tissue microarray with a phospho-specific pan-AKT (Ser473) antibody, which revealed elevated staining in 21 of 31 (68%) ovarian carcinomas. Phospho-AKT staining was associated with that of phospho (active)-mTOR in 27 of 31 (87%) ovarian tumors, with 17 (55%) tumors showing elevated phospho-mTOR positivity. We tested the effects of AKT/mTOR activation on the therapeutic sensitivity of ovarian cancer cells. Pretreatment of SKOV3 cells, which exhibit constitutive AKT activity under low serum conditions, with the PI3K inhibitor LY294002 augmented cisplatin-induced apoptosis. In contrast, ovarian cancer cell lines OVCAR4 and OVCAR5, which have low basal levels of AKT activity, did not show increased cisplatin-induced apoptosis when pretreated with LY294002. In addition, inhibition of mTOR activity with rapamycin resulted in G1 arrest in SKOV3 cells, but not in OVCAR4 or OVCAR5 cells. Collectively, these findings indicate that active AKT and downstream mTOR represent potentially important therapeutic and/or chemopreventive targets in ovarian cancer.
Multiple AKT substrates have been implicated in oncogenesis (reviewed in Testa and Bellacosa, 2001; Cantley, 2002) . Activated AKT exerts antiapoptotic effects, positively regulates NF-kB transcription, modulates angiogenesis, enhances telomerase activity, promotes tumor invasion/metastasis, and antagonizes cell cycle arrest. AKT also mediates mRNA translation by phosphorylating mTOR (mammalian target of rapamycin) protein kinase. Activation of mTOR leads to the phosphorylation of eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), dissociating 4E-BP1 from the mRNA cap binding protein eIF4E to promote protein synthesis (Sonenberg and Gingras, 1998) . mTOR also affects the activity of the ribosomal protein S6 kinase (p70S6K) and subsequent phosphorylation of S6 ribosomal protein to stimulate protein translation, and p70S6K has been shown to be required for cell growth and G1 cell cycle progression (Pullen and Thomas, 1997) .
AKT perturbations may play an important role in human cancer. AKT1 kinase activity is frequently increased in breast and prostate cancers and is associated with a poor prognosis (Sun et al., 2001) . Activation of the AKT2 kinase has been observed in B40% of ovarian cancers (Yuan et al., 2000) and B35% of pancreatic tumors (Altomare et al., 2002) , and increased AKT3 activity has been reported in estrogen receptor-deficient breast cancer and androgen-insensitive prostate cancer cell lines (Nakatani et al., 1999) . Analysis of upstream components of the phosphatidylinositol 3-kinase (PI3K)/ AKT pathway has shown that downregulation of PTEN and/or activation of PI3K, either through autocrine or paracrine stimulation of growth factor receptors, contributes to AKT activation in human tumors (Nakatani et al., 1999; Yuan et al., 2000; Sun et al., 2001; Altomare et al., 2002) . Moreover, in ovarian cancer, overexpression of the catalytic domain of PI3K has been reported (Shayesteh et al., 1999) .
In this investigation, we performed an immunohistochemical analysis with an antibody against phosphorylated Ser473 of AKT to recognize the active forms of all three AKT isoforms and verify the presence of high levels of phosphorylated (active) AKT in tumor cells compared to stroma and normal ovarian tissue. Immunostaining of an ovarian cancer tissue microarray revealed that 21 of 31 (68%) ovarian carcinomas stained positively ( þ þ or þ þ þ ) for phospho-AKT (Figure 1a) , implying that when the various AKT isoforms are assessed collectively, a considerably higher percentage of ovarian cancers have activation of AKT than has been suggested by the assessment of isoformspecific AKT activity alone. The high percentage of ovarian tumors that exhibited strong immunostaining with antibodies against phosphorylated AKT is similar to that recently observed in severely dysplastic nevi and melanomas (Dhawan et al., 2002) , and head and neck tumors (Gupta et al., 2002) .
To determine if AKT activation in our set of ovarian carcinomas paralleled mTOR activation, we used an antibody directed at phosphorylated mTOR Ser2448, which recognizes the active form of the mTOR kinase ( Figure 1a ). In total, 17 of 31 (55%) tumors analysed have activation of both phospho-AKT and phosphomTOR and 10 of 31 tumors have activation of neither AKT nor mTOR. Thus, altogether an association between phospho-AKT staining and phospho-mTOR staining was observed in 27 of 31 ovarian tumors (87%) (Figure 1b) . Statistical assessment of the immunohistochemical staining summarized in Figure 1b revealed that phospho-mTOR positivity is significantly associated with phospho-AKT positivity (Fisher's exact test, Pvalue o0.0001). The strong association between AKT and mTOR phosphorylation was confirmed by Western blot analysis (Figure 2 ) using an independent group of ovarian tumors. As additional evidence for AKT activity, we found that phosphorylation of a second downstream substrate of AKT signaling, namely glycogen synthase kinase 3 (GSK3)-beta, correlated with that of AKT, with an association between phospho-AKT and phospho-mTOR in 29 of 35 (83%) tumors and an association between phospho-AKT and phospho-GSK3-beta in 31 of 35 (89%) tumors. The close association between activation of AKT and mTOR suggests that a subset of human ovarian tumors may be strongly dependent on AKT/mTOR signaling for tumor progression. Thus, pharmacologic inhibition of mTOR may be therapeutic for ovarian cancer patients with aberrant AKT/mTOR signaling, as has been suggested by recent studies with Pten-deficient mice showing that AKT activation is an important factor in predicting which tumors will be sensitive or resistant to mTOR inhibition Podsypanina et al., 2001 ).
Accordingly, we tested the effects of AKT activation on the therapeutic sensitivity of human ovarian cancer cells. To define appropriate in vitro models with high and low dependence on AKT activity, ovarian cancer cell lines were grown under normal growth conditions (10% FBS), then deprived of serum overnight ( Figure 3a ). SKOV3 ovarian cancer cells exhibited high levels of AKT activity upon serum deprivation, which is indicative of constitutive AKT activity. PTEN protein has been shown to be low in SKOV3 cells (Arboleda et al., 2003) and is likely to contribute to the increased levels of constitutive AKT activity in this cell line. In contrast, OVCAR4 and OVCAR5 cells had low basal Immunohistochemical staining of a representative human ovarian tumor from a tissue microarray showing the absence of staining in a negative control (commercially available blocking peptide that is specific to the epitope recognized by the phosphorylated Ser473 AKT antibody, Cell Signaling Technology), and strong positivity (brown stain) for phospho-AKT (P-AKT) and phospho-mTOR (P-mTOR) in tumor cells, but not in surrounding stroma. Ovarian tumor tissue microarrays (TMA) were provided by the Biosample and Tissue Procurement Core Facility at Fox Chase Cancer Center. Slides containing formalin-fixed, paraffin-embedded samples were deparaffinized, hydrated in water, and subjected to antigen retrieval in 10 mM citrate buffer, pH 6.0. Primary antibodies, phospho-AKT Ser473 or phospho-mTOR Ser2448 (Cell Signaling Technology), were detected with biotinylated secondary antibodies. Negative controls were incubated with primary antibody preabsorbed with blocking peptide (Cell Signaling Technology). Tissue sections were stained with DAB chromagen and counterstained with hematoxylin. Surrounding non-neoplastic stroma served as an internal negative control for each slide. The slides were scored semiquantitatively. A score of 0 indicated no staining, 0.5 was generally negative with some focal staining, 1 was indicative of weak focal staining, 2 indicated clearly positive staining, and a score of 3 was intensely positive. (b) Expression of phospho-mTOR is associated with that of phospho-AKT in ovarian tumors. Tabulation of overall immunohistochemical staining of ovarian tumor TMAs with antibodies against phospho-AKT and phosphomTOR. Tumors with strong staining (m) of þ 2 or þ 3 were grouped, and tumors with weak or no staining (7) were grouped Figure 2 Western blot analysis illustrating the association between active AKT and phosphorylated downstream substrates mTOR and GSK3-beta in ovarian tumor lysates. For detection of protein expression, 20-30 mg of protein was subjected to Western blot analysis. Primary antibodies included actin (Santa Cruz Biotechnology), phospho-AKT Ser473, phospho-mTOR Ser2448, and phospho-GSK3-beta (all from Cell Signaling Technology). Actin expression was used as a control to assess for protein extract quality and loading. Antigen-bound antibody was detected by chemiluminescence. Asterisks (*) indicate tumors with high expression of phospho-AKT, phospho-mTOR, and phospho-GSK3-beta levels of AKT activity under identical conditions. In all three cell lines, AKT activity was inducible in response to epidermal growth factor (EGF) and insulin (data not shown), and phosphorylation of AKT was diminished upon treatment with the specific PI3K inhibitor LY294002 (Figure 3a) , confirming that AKT activation is PI3K-dependent. LY294002 inhibited phosphorylation of p70S6K in SKOV3 cells (Figure 4c ), but had little effect in OVCAR4 and OVCAR5 cells, the latter displaying very low levels of phosphorylated p70S6K even without the addition of LY294002 (not shown).
We next showed that inhibition of PI3K/AKT signaling induces apoptosis selectively in ovarian cancer cells with constitutive AKT activity.
DNA fragmentation analysis showed that pretreatment of SKOV3 cells with LY294002 augmented the apoptotic response induced by cisplatin (Figure 3b) . Western blot analysis of the 89-kDa poly(ADP-ribose) polymerase (PARP) proteolytic cleavage product also provided evidence that LY294002 induced apoptosis selectively in ovarian cancer cell lines with constitutive AKT activity and that pretreatment of cells with LY294002 augmented cisplatin-induced apoptosis (Figure 3c ). These experiments indicate that constitutive activation of AKT in SKOV3 cells promotes cell survival.
Our findings are consistent with previous reports regarding the role of the AKT signaling in response (Page et al., 2000; Hu et al., 2002) . In vitro and in vivo ovarian cancer models that combined LY294002 with paclitaxel increased the efficacy of chemotherapy on tumor cell growth and dissemination compared to either agent alone (Hu et al., 2002) , and PI3K inhibition in combination with paclitaxel markedly reduced ascites formation, a common occurrence in ovarian cancer.
Ovarian cancer cell lines with either constitutive AKT1 activity or AKT2 gene amplification have been shown to be highly resistant to paclitaxel compared to cells with low AKT levels (Page et al., 2000) . Similarly, we used adenoviral-mediated infection to express a constitutive active (myristoylated) form of AKT in OVCAR4 and OVCAR5 cells to determine the effect on cisplatin-induced cell death, and found that constitutive AKT activity in OVCAR4 and OVCAR5 cells increased resistance to cisplatin (data not shown). Collectively, these data suggest that increased AKT signaling in cells with normally basal levels of AKT activity protects against apoptosis.
Considering the association between phospho-AKT and phospho-mTOR activity and previous reports suggesting that AKT activity is an important factor in predicting which tumors will be sensitive or resistant to mTOR inhibition Podsypanina et al., 2001) , we analysed ovarian cancer cell lines with high or low levels of AKT activity for potential sensitivity to rapamycin-induced G1 arrest. Figure 4a and 4b show that SKOV3 cells are responsive to rapamycin-induced G1 arrest, and that the effect of rapamycin on cell cycle progression was similar to that of LY294002; that is, the combination of PI3K and mTOR inhibition did not have an additive effect with regard to cell cycle arrest. In contrast, neither LY294002 nor rapamycin had any effect on cell cycle progression in OVCAR4 or OVCAR5 cells.
Western blots of protein lysates from SKOV3 cells (Figure 4c) show that phoshorylation of downstream p70S6K (Thr389) and S6 ribosomal protein (Ser240/ 244) was inhibited in cells treated with LY294002 and/or rapamycin. Thus, protein translation was affected in response to treatment in SKOV3 cells. Expression of the cyclin-dependent kinase inhibitors p27 Kip1 and p21 Cip1 was low in SKOV3 cells with constitutive AKT activity and upregulated in response to LY294002 and/or rapamycin treatment (Figure 4c ). In contrast, phospho-p70S6K, phospho-S6 ribosomal protein, p27 Kip1, or p21 Cip1 expression did not change in OVCAR4 or OVCAR5 cells (data not shown). These findings suggest that PI3K/AKT/mTOR signaling plays a critical role in regulating G1/S progression in SKOV3 cells, but not in OVCAR4 or OVCAR5 cells. Collectively, these findings underscore the contention that active AKT is a potentially important target for the development and application of chemotherapeutic agents that induce cytotoxic sensitivity in ovarian tumors.
In conclusion, AKT is a major mediator of survival signals that protect ovarian cancer cells from undergoing apoptosis and is frequently activated in primary ovarian carcinomas. Thus, pharmacologic agents that inhibit AKT signaling might preferentially kill tumor cells that have a dependence on AKT activity for survival not shared by normal cells (Brognard et al., 2001; West et al., 2002) . Collectively, these data provide a strong rationale for identifying inhibitors or modulators of the PI3K/AKT/mTOR pathway, with the intention of developing novel chemopreventive/ chemotherapeutic strategies directed at ovarian cancers exhibiting AKT activation.
